『Global Biotech - Is America Falling Behind?』のカバーアート

Global Biotech - Is America Falling Behind?

Global Biotech - Is America Falling Behind?

無料で聴く

ポッドキャストの詳細を見る
In this episode, Steve Vinson dives into a provocative article by US Senator Todd Young, exploring the shifting landscape of global biotech innovation. With China's rapid advances—highlighted by a breakthrough lung cancer drug—Steve analyzes the factors behind America's waning leadership, from fragmented policy and regulatory uncertainty to funding challenges and talent migration. Drawing on his own industry experience, Steve discusses the impact of immigration crackdowns, supply chain vulnerabilities, and the long-term effects of reshoring manufacturing. Listeners will gain insight into the political and economic forces shaping biotech's future, the importance of global collaboration, and the risks of falling behind. Whether you're a new entrepreneur or a technical professional in life sciences, this episode offers actionable perspectives and invites you to join the conversation on how the US can reclaim its edge in biotech innovation. Link to Senator Youg's article: https://www.foreignaffairs.com/united-states/how-america-can-win-biotech-race# MUSIC: Acid Jazz-Kevin MacLeod used under the Creative Commons Attribution 4.0 International License Detailed Show Notes Main Discussion Points China's biotech innovation and breakthrough lung cancer drug US policy fragmentation and regulatory uncertainty Biotech funding challenges and investor risk Impact of immigration crackdowns on talent Supply chain vulnerabilities and tariffs Reshoring US manufacturing and its costs Lessons from the semiconductor industry Call for audience insights on political and trade issues Key Quotes "China's catching up doesn't bother me—it's not a zero-sum game." "What concerns me more is the US falling behind." "Investors want to predict risk, but uncertainty is driving capital elsewhere." "We don't want a brain drain; we need that talent." "Significant investments are being made, but it will take years for new facilities to come online." Call-to-Action (CTA) Subscribe to The Life Science Effect, leave a review, and share your thoughts at steven.vinson@bpm-associates.com. Visit thelifescienceeffect.com for more episodes and resources. TRANSCRIPT: You are about to experience the Life Science Effect. Season 2. Brought to you by our presenting sponsor, BPM Associates. Extraordinary people. Relationships that matter. Important change for a better world. The joy of belonging. Life. Science. Leadership. Welcome to the next episode. I just read this piece in Foreign Affairs, and it's called "How America Can Win the Biotech Race." It's by Todd Young, who happens to be a senator from Indiana, United States senator, a Republican from Indiana. It was published on October 15th, so it's relatively recent. Key points that I found and what caught my eye was they're talking about a Chinese biotech company that developed a lung cancer drug that outperformed Merck's best-in-class treatment. And it sort of is a signal of China's rapid innovation. The US seems to be—now remember, this is a United States Senator, a Republican—so a lot of this is, you would have to take it from a political point of view. And so I'm not going to say I agree with everything in this article. I would have to do a little more assessment and research. So when you hear me saying the US is losing ground in biotech because of fragmented policy and regulatory hurdles and stagnant funding, I don't know 100% how much of that is accurate. However, I would say there is fragmented policy. I would agree with that. You've heard me say it on this podcast where there's uncertainty in what the regulatory landscape is going to look like given the new administration. And since I first published those episodes earlier this year, things have not gotten better in those terms. And the funding has dried up for biotech. Some of it's starting to make a comeback, but a lot of the funding dried up because investors expect a return and they expect to be able to predict the return, or at least predict the risk. So there's always risk and they want to be able to predict what that risk is going to look like. With the new administration, a lot of things remain unclear with tariffs, how the FDA is going to approach regulation, how they're going to view certain scientific data. There's uncertainty there. So the investors are looking for somewhere else to put their capital. So China, in the meanwhile, hasn't had a big change like we have. And they've been investing billions of dollars. And they're able to, with their system, they're able to pick winners and like who's likely to be a winner and redirect capital to those things that look most promising. And so how did they hit me? Well, I was a little bit surprised how quickly China's catching up, but only a little because I've known China was making these big investments. And I've known that they've been attracting a lot of talent into the industry. And it is a little bit annoying because the US has historically led ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません